Science Translational Medicine 2018-04-04

Fighting leukemia with “duel”-targeted therapy

Tríona Ní Chonghaile

文献索引：10.1126/scitranslmed.aat3887

摘要

Combining BCL-2 inhibitor venetoclax with monoclonal CD20 antibody rituximab greatly enhances progression-free survival compared with bendamustine-rituximab in a phase 3 trial of relapsed or refractory chronic lymphocytic leukemia patients.